PROFILPELAJAR.COM

Lu AF28996

Lu AF28996
Clinical data
Other namesLu-AF28996; LuAF28996; Lu-AF-28996
Routes of
administration		Oral[1][2]
Drug classDopamine receptor agonist; Dopamine D1-like and D2-like receptor agonist; Antiparkinsonian agent

Lu AF28996 is a dual dopamine D1-like and D2-like receptor agonist which is under development for the treatment of Parkinson's disease.[1][3][2][4][5][6][7] It is taken orally.[1][2] The drug is a prodrug that is reversibly converted into an active form.[2] Lu AF28996 was first described in the scientific literature by 2021.[4] It is under development by Lundbeck.[1][3] As of April 2025, the drug is in phase 1 clinical trials.[1][3] The chemical structure of Lu AF28996 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "Lu AF 28996". AdisInsight. 28 April 2025. Retrieved 28 January 2026.
  2. ^ a b c d "Lu AF28996". ALZFORUM. 17 April 2026. Retrieved 7 June 2026.
  3. ^ a b c "Delving into the Latest Updates on Lu-AF28996 with Synapse". Synapse. 3 December 2025. Retrieved 28 January 2026.
  4. ^ a b McFarthing K, Rafaloff G, Baptista MA, Wyse RK, Stott SR (2021). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update". Journal of Parkinson's Disease. 11 (3): 891–903. doi:10.3233/JPD-219006. PMC 8461678. PMID 34151864.
  5. ^ Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S (2023). "Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment". Clinical Parkinsonism & Related Disorders. 9 100212. doi:10.1016/j.prdoa.2023.100212. PMC 10366643. PMID 37497384.
  6. ^ McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. (2024). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update". Journal of Parkinson's Disease. 14 (5): 899–912. doi:10.3233/JPD-240272. PMC 11307066. PMID 39031388.
  7. ^ Gros P, Garcia LA, Fox SH (May 2025). "Experimental Therapeutics in Parkinson's Disease: A Review". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.